Fresenius Kabi Canada has received a Health Canada Notice of Compliance (NOC) for Otulfi™* an Ustekinumab Biosimilar
Fresenius Kabi Canada proudly announces the recent Health Canada Notice of Compliance (NOC) for OtulfiTM, an ustekinumab biosimilar indicated for Crohn's disease, ulcerative colitis, plaque psoriasis ...
Drug Store News11d
Fresenius inks licensing agreement to commercialize proposed Aflibercept biosimilar
Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...
Business Insider1mon
Ori Biotech and Fresenius Kabi Collaborate to Advance Modular, Scalable Manufacturing of Cell and Gene Therapies
In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral ...
Joplin Globe1mon
Fresenius Kabi Launches Epinephrine Injection, USP Expanding U.S. Pharma Portfolio
In Biopharma, Fresenius Kabi offers cutting-edge biosimilars for autoimmune diseases and oncology. With leading market positions in Clinical Nutrition, a broad portfolio of enteral and parenteral ...
Stockhouse11d
Fresenius Kabi Canada has received a Health Canada Notice of Compliance (NOC) for Otulfi(TM)* an Ustekinumab Biosimilar
Fresenius Kabi, an operating company of Fresenius, is further continuing its momentum in Canada, striving to expand its strong Biopharma portfolio. This expansion is a substantial cornerstone of ...